Table 3.
The effect of body mass index (BMI) (≤ 26 kg/m2 or > 26 kg/m2) on efficacy outcomes in patients receiving biphasic insulin aspart 30 (BIAsp 30) and metformin combination therapy or BIAsp 30 monotherapy (ITT LOCF).
| Endpoints | BMI ≤ 26 kg/m2 | BMI > 26 kg/m2 | ||||
|---|---|---|---|---|---|---|
| BIAsp 30 + Met (N = 84) |
BIAsp 30 (N = 85) |
p value | BIAsp 30 + Met (N = 46) |
BIAsp 30 (N = 42) |
p value | |
| HbA1c change from baseline, % (mean ± SD) | − 1.71 ± 1.72 | − 1.21 ± 1.45 | 0.3273 | − 1.78 ± 1.53 | − 1.53 ± 2.89 | 0.8557 |
| Patients who achieved HbA1c target (< 7%), n (%) | 33 (47.83%) | 20 (28.17%) | 0.0165* | 26 (61.90%) | 18 (48.65%) | 0.2366 |
| Patients achieving HbA1c < 7% without hypoglycemia or weight gain, n (%) | 14 (20.29%) | 5 (6.85%) | 0.0187* | 12 (27.91%) | 12 (32.43%) | 0.6597 |
BMI body mass index, ITT intention-to-treat, LOCF last observation carried forward, HbA1c glycated hemoglobin, SD standard deviation.
*p < 0.05.